Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran

BACKGROUND: The prevalence of hepatitis C in Iran is 1% and 18% in general population and thalassemia patients respectively. The cost effectiveness analysis of adding Ribavirin to Peginterferon alfa-2a (PEG IFN alfa-2a) as a combination treatment strategy of chronic hepatitis C in thalassemia patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehrazmay, Alireza, Alavian, Seyed Moayed, Moradi-Lakeh, Maziar, Mokhtari Payam, Mahdi, Hashemi-Meshkini, Amir, Behnava, Bita, Miri, Seyyed Mohammad, Karimi Elizee, Pegah, Tabatabaee, Seyed Vahid, Keshvari, Maryam, Bagheri Lankarani, Kamran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830516/
https://www.ncbi.nlm.nih.gov/pubmed/24282420
http://dx.doi.org/10.5812/hepatmon.10236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830516/
https://www.ncbi.nlm.nih.gov/pubmed/24282420
http://dx.doi.org/10.5812/hepatmon.10236

Ejemplares similares